Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 142 Publications

20 Customer Reviews

  • Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

    Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MVzDfZRwfG:6aXOgRZN{[Xl? MY[1NEDPxE1? NEW4WXQ1QCCq MVzEUXNQ M1Tpe2tqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> M{niXlExPDl7NkSz
OVCA 429 M{P1bWZ2dmO2aX;uJGF{e2G7 MWSzNFAhdk1? Mmr5OFghcA>? MULEUXNQ MYTEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= M2fuN|ExQTl7N{[2
RPMI8226 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PzZVExOCCwTR?= MoHQOFghcA>? MVnEUXNQ NIXYfFRKSzVyPUOwJI5O MWWxNVMxPjR6OR?=
Dox40 M4rqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNFAhdk1? M2X2eFQ5KGh? M2\iU2ROW09? M4HKU2lEPTB;NECgcm0> MYmxNVMxPjR6OR?=
MR20 NGjofFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnnfFgyODBibl2= NYXkdHlxPDhiaB?= MmDlSG1UVw>? M1HWcWlEPTB;MkCgcm0> NYK3OIRqOTF|ME[0PFk>
LR5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jqXlExOCCwTR?= NGnPUmY1QCCq MX;EUXNQ NWOyWZdPUUN3ME2yNEBvVQ>? MUWxNVMxPjR6OR?=
U266 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO4WZEyODBibl2= M4X1bFQ5KGh? MUnEUXNQ NIXE[Y9KSzVyPUOgcm0> M1ztclEyOzB4NEi5
IM-9 NIrB[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrJVocyODBibl2= NWDERmtbPDhiaB?= NELHWpVFVVOR M3fEc2lEPTB;NjDuUS=> NGLSfW0yOTNyNkS4PS=>
Hs Sultan MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBbW4yODBibl2= MUi0PEBp NHL6UItFVVOR NIK1fYFKSzVyPUKwJI5O NXXpU5puOTF|ME[0PFk>
PAM-LY2 MXnGeY5kfGmxbjDBd5NigQ>? NVLYXndxOTByIH7N NXPtT3l1OTJiaB?= M4r0d2ROW09? NVHheXRUUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> M3fPe|EyOzVyOUGz
PAM 212 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTOT3AyODBibl2= Ml75O|IhcA>? NXixWIlFTE2VTx?= MUXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M1PaWVEyOzVyOUGz
PAM-LY2 NYDsSmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxNFAhdk1? Ml\NO|IhcA>? NGPWNFlFVVOR MVnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXWxNVM2ODlzMx?=
B4B8 NU\JeW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNFAhdk1? NEm2V4s4OiCq NGLXWVVFVVOR MkPaTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MX2xNVM2ODlzMx?=
B7E3 M1vTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDDZnJKOTByIH7N M2S4PFczKGh? M4nIPGROW09? M1LJS2lvcGmkaYTzJINmdGxidnnhZoltcXS7 M3XvbFEyOzVyOUGz
UM-SCC-9 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDNVAxKG6P Mkn1O|IhcA>? NUHzT3FWTE2VTx?= MXHJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M1HwXVEyOzVyOUGz
UM-SCC-11B MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULqZo9GOTByIH7N NFfrV5Q4OiCq M1LMUmROW09? NH3ndJdKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NVLFepdHOTF|NUC5NVM>
H460 Mni5SpVv[3Srb36gRZN{[Xl? MlHFNVAh|ryP NWr0OYhPOjRiaB?= M3HlcmROW09? NGDx[pZKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 MVWxNlQ6OjFzNx?=
U266 M4HFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPlOVAxKG6pL33s NXTjN4k3PDhiaB?= MWrEUXNQ MnfHTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVvsU3pWOTJ4M{G2NVk>
ARH77 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTCRmNKPTByIH7nM41t NET1dFk1QCCq NV62XHlbTE2VTx?= MXHJcohq[mm2czDj[YxtKGe{b4f0bC=> MYqxNlY{OTZzOR?=
WAD-1 M2L6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJZVUxOCCwZz;tcC=> NWHG[XlCPDhiaB?= M4nvPGROW09? MVnJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn;CNVI3OzF4MUm=
U266/LR7 NEnPTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrcJo4PTByIH7nM41t MX:0PEBp MVPEUXNQ M3XlWGlvcGmkaYTzJINmdGxiZ4Lve5Rp NXntcWJpOTJ4M{G2NVk>
U266/dox4 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi1NFAhdmdxbXy= MUe0PEBp MWHEUXNQ MmHCTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M1jCelEzPjNzNkG5
RPMI8226/LR5 NHzBb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjnOmY2ODBibnevcYw> NU\VV4t5PDhiaB?= M{nzc2ROW09? NUTCS|FGUW6qaXLpeJMh[2WubDDndo94fGh? M4jkRlEzPjNzNkG5
H460 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jo[lExKM7:TR?= M37wbFczKGh? M3qy[2ROW09? MWPJR|UxRTFyMDDuUS=> Ml[2NVI3OzF4MkC=
H358 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNEDPxE1? M3fBVlczKGh? MVTEUXNQ M{HMRWlEPTB;N{Cgcm0> Mlv4NVI3OzF4MkC=
H322 M{TuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nJSVExKM7:TR?= NVP1[YhqPzJiaB?= MXHEUXNQ NInkeXFKSzVyPU[yNEBvVQ>? NHvQS|QyOjZ|MU[yNC=>
H460 MoLwSpVv[3Srb36gRZN{[Xl? MlPBNVAxKG6P MnGxNlQhcA>? NFTXT2RFVVOR NYLCZVZFUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= NFzydmIyOjZ|MU[yNC=>
LNCap-Pro5 M1;IVmZ2dmO2aX;uJGF{e2G7 MVSxJO69VQ>? NVWwbohuPCCq MmLWSG1UVw>? NXHLc5lGW3SjYnnsbZpmeyCyNUO= NHvrSVcyPDZzMkWzNi=>
T29 MVnBdI9xfG:|aYOgRZN{[Xl? M3TYS|UxKG6P MmrjOFghcCB? NYqxOJlbTE2VTx?= NXvoeVNoUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFfYcXYyPjd5OEG3PS=>
T29Kt1 NULxZ|dMSXCxcITvd4l{KEG|c3H5 NYHpR5dnPTBibl2= MkXOOFghcCB? MY\EUXNQ NVntVJlRUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX7w[mhTOTZ5N{ixO|k>
HCT116 MnrNRZBweHSxc3nzJGF{e2G7 MXu1NEBvVQ>? NVTXSGRMPDhiaDC= M4PnbmROW09? MU\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4OybFE3Pzd6MUe5
HKe-3 M{LvWmFxd3C2b4Ppd{BCe3OjeR?= NInJOlg2OCCwTR?= Mk\MOFghcCB? MmnaSG1UVw>? M2fCWWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHPSe5oyPjd5OEG3PS=>
NB-1691 M4TGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjT|kyKM7:TR?= M4XLdlczKGh? NF3YWmFKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MkTtNVc3QDl4OES=
CHLA-255 NEHoOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DOPFEh|ryP NITPWGU4OiCq NEf0[|FKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NWrNXW1EOTd4OEm2PFQ>
SK-N-AS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Mdoc3OSEQvF2= NWHMOlRxPzJiaB?= MWTJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn Mn\VNVc3QDl4OES=
NB-1691 MYTGeY5kfGmxbjDBd5NigQ>? MXWxNEBvVQ>? NV;QUXc1OjRiaB?= NIn1Z2FUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm M3Hh[VE4Pjh7Nki0
CHLA-255 NXf3NnpYTnWwY4Tpc44hSXO|YYm= MYmxNEBvVQ>? NGX5b3YzPCCq MVfNc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? MnnNNVc3QDl4OES=
RPMI 8226 NVzDc2hpTnWwY4Tpc44hSXO|YYm= NUnMeGd2OjBibl2= Ml\GPEBp MnHSV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MljrNVk1OzZyNUC=
MM.1S NXzYTFV[TnWwY4Tpc44hSXO|YYm= NFjrXIgzOCCwTR?= MXK4JIg> MlWyV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MY[xPVQ{PjB3MB?=
U266 M3HPRmZ2dmO2aX;uJGF{e2G7 M33XUFIxKG6P MkO0PEBp NFG0Z4NUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MkfFNVk1OzZyNUC=
OPM1 NUDY[YtbTnWwY4Tpc44hSXO|YYm= MnvTNlAhdk1? NUHTN2h5QCCq MYPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> Mm[1NVk1OzZyNUC=
INA6 NITod5dHfW6ldHnvckBCe3OjeR?= MmDUNlAhdk1? M3rC[lghcA>? MW\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NUDXc2YzOTl2M{[wOVA>
OPM2 M2rRZWZ2dmO2aX;uJGF{e2G7 NXjXepRSOjBibl2= MUS4JIg> NH2ydWtUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NVXvVZlROTl2M{[wOVA>
RPMI 8226 NWXaeW9pTnWwY4Tpc44hSXO|YYm= MkTpNlAhdk1? NHvOb|M5KGh? M{Lad2lv\HWlZYOgSG5CKHO7boTo[ZNqew>? NUnodWV3OTl2M{[wOVA>
BaF/3 NU\1NmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zkTlExOCCwTR?= NH\1Zng1QCCq MoPmTWM2OD14LkKgcm0> NUS2dIh7OjB|MEW2PVI>
BaF/3-p210 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rLb|ExOCCwTR?= NHnWT3E1QCCq NITaTHFKSzVyPUSuO{BvVQ>? M1zDNVIxOzB3Nkmy
TCC-S NXvMbFlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHRNVAxKG6P MnnNOFghcA>? MkHoTWM2OD1{Lkigcm0> NULvflhvOjB|MEW2PVI>
BaF/3 NF3Yb3lHfW6ldHnvckBCe3OjeR?= M{fnSVYhdk1? MmXFOFghcA>? MknZTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 NWHyb2FEOjB|MEW2PVI>
BaF/3-p210 M1v2fmZ2dmO2aX;uJGF{e2G7 MUS2JI5O NH\kRnQ1QCCq NVfPe2xpUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? MXWyNFMxPTZ7Mh?=
BaF/3-p210 MUjGeY5kfGmxbjDBd5NigQ>? NHHPTJo3KG6P MmnPNlQhcA>? MmHTVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? MXiyNFMxPTZ7Mh?=
Raji NXzQe29iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxJO69VQ>? M2XS[lI1KGh? MoHrVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MVyyNVE4ODl6OB?=
LCL-1 M3zjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\kNUDPxE1? MYGyOEBp MmPxVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M1POZ|IyOTdyOUi4
LCL-2 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknaNUDPxE1? NYHGXZIxOjRiaB?= Mn7kVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M160O|IyOTdyOUi4
BJAB NHi1d3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XRelEh|ryP NUDBdXdXOjRiaB?= MVTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M3HIVVIyOTdyOUi4
SNT-13 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3znR|Eh|ryP NEDXWGgzPCCq M4fuVXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M2rz[VIyOTdyOUi4
SNT-16 M{LTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxJO69VQ>? MoDmNlQhcA>? NUjKdpk4WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MVWyNVE4ODl6OB?=
Jurkat NVO2PGxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxJO69VQ>? MlO0NlQhcA>? M4nOTHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3rle|IyOTdyOUi4
KAI-3 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xJO69VQ>? MXiyOEBp NYjGWlZ4WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MW[yNVE4ODl6OB?=
SNK-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;iXoMyKM7:TR?= M{LudlI1KGh? M4PU[XJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUCyNVE4ODl6OB?=
KHYG-1 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPyPXAyKM7:TR?= MVGyOEBp MWfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MlHkNlEyPzB7OEi=
SNT-16 NVq3cYVbSXCxcITvd4l{KEG|c3H5 MUexJO69VQ>? Mkn3OkBp NVTXdYRoUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFHUeXAzOTF5MEm4PC=>
Jurkat NXfXd3ZDSXCxcITvd4l{KEG|c3H5 Mnm4NUDPxE1? NWf5[3hJPiCq MoDiTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFTlNmgzOTF5MEm4PC=>
KAI-3 M2rSUWFxd3C2b4Ppd{BCe3OjeR?= MVuxJO69VQ>? M1;vbFYhcA>? MXLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1m4fVIyOTdyOUi4
KHYG-1 NFP3ZWhCeG:ydH;zbZMhSXO|YYm= NXLGNnh2OSEQvF2= MknGOkBp MnnHTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUWyNVE4ODl6OB?=
SNT-13 Mn\NRY51cX[rcnHsJGF{e2G7 NF;BWG8yKM7:TR?= MlTqNlQhcA>? NIrFWXZKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NHjy[nozOTF5MEm4PC=>
SNT-16 MXLBcpRqfmm{YXygRZN{[Xl? NHH3bW4yKM7:TR?= NH;PeG4zPCCq NF\jPJhKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? Ml\JNlEyPzB7OEi=
KAI-3 Mk\mRY51cX[rcnHsJGF{e2G7 MoTUNUDPxE1? MXqyOEBp NVTnNFRyUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M2nWb|IyOTdyOUi4
SNK-6 NV62RpFuSW62aY\pdoFtKEG|c3H5 NEDK[JgyKM7:TR?= MknBNlQhcA>? Ml3iTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NEjyfVUzOTF5MEm4PC=>
RAW 264.7 NIjjXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7RdpUyODBibl2= NIO5PIM1QCCq MYrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MmH1NlI1OjdzNUS=
A375 NWfEWlhkSXCxcITvd4l{KEG|c3H5 MY[xNEBvVQ>? NWjXdGk{OjRiaB?= MXTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1XTfVI{ODd7MEiz
BLM Mo\jRZBweHSxc3nzJGF{e2G7 M2P2U|ExKG6P MoCwNlQhcA>? NXvzcHZ6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHX0VnkzOzB5OUC4Ny=>
A375 M2LXcmF2fG:yaHHnfUBCe3OjeR?= MYqxNEBvVQ>? M4TweVEzKGh? MXjJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M1HJN|I{ODd7MEiz
BLM M4TuS2F2fG:yaHHnfUBCe3OjeR?= NELSVZEyOCCwTR?= M2ToNlEzKGh? NFjLTXJKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NXzoVHJiOjNyN{mwPFM>
H1299 M3XPc2Fxd3C2b4Ppd{BCe3OjeR?= M3jiSlgxKG6P Mn;SNlQhcA>? NYfrbIEyTE2VTx?= MUPT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? NUHvTpRlOjV|MkO2PVM>
Hut-78 NVf6ZnJQTnWwY4Tpc44hSXO|YYm= MnK2NVAxKG6P MXOyOEBp NXW5ZVFmTE2VTx?= MljTSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w Ml7sNlU3QDF|M{W=
H9 NV3MTXdmTnWwY4Tpc44hSXO|YYm= M2jFUFExOCCwTR?= NXjQWYQ{OjRiaB?= MnXrSG1UVw>? NWS2NHgzTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u MlzsNlU3QDF|M{W=
HH NFzYO|RHfW6ldHnvckBCe3OjeR?= NYTJfnZNOTByIH7N NWPpOFR7OjRiaB?= MnjOSG1UVw>? NV:wd2I6\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u MoKwNlU3QDF|M{W=
Hut-78 MXHNbYdz[XSrb36gRZN{[Xl? Mlq4NVAxKG6P MmraNlQhcA>? MmTCSG1UVw>? M1q5O3Jm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= NED0clczPTZ6MUOzOS=>
HH NUe5OmFMVWmpcnH0bY9vKEG|c3H5 NGezNmcyODBibl2= NV[3eIQ1OjRiaB?= MUnEUXNQ NWDwTGlmWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> NHX2[|gzPTZ6MUOzOS=>
U937 NYLNb2c2TnWwY4Tpc44hSXO|YYm= NG\nUo8yODBibl2= Ml7uOkBp M{fNTGlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? M3jQUlI2PzlzNEe3
human PBMC NWOzUYZoTnWwY4Tpc44hSXO|YYm= M{fYcFExOCCwTR?= NVy0Wo1nOjRiaB?= NUnHOGZHUW6mdXPld{BKVC16IILlcIVie2V? NVHBZXYxOjV5OUG0O|c>
ES6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XoOWlEPTB;MD6wNFIyKG6P MUPTRW5ITVJ?
SK-UT-1 NVHhWY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKzd4lJUUN3ME2wMlE3OyCwTR?= MXPTRW5ITVJ?
SH-4 NV\RWpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUezJI5O NVfmOFBCW0GQR1XS
TE-9 NXjRV|RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\5eWlEPTB;MD6xPFIhdk1? M3PlRXNCVkeHUh?=
A253 NYraRYc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;jW2lEPTB;MD6yNFghdk1? NWS3NVZuW0GQR1XS
no-10 NXvRNXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;x[WlEPTB;MD6yNUBvVQ>? MorIV2FPT0WU
MMAC-SF MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP1d4tKSzVyPUCuNlE3KG6P MoXFV2FPT0WU
A101D NFK4NI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PQemlEPTB;MD6yNlUhdk1? NXHuOYUyW0GQR1XS
NTERA-S-cl-D1 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMkSzJI5O MnHPV2FPT0WU
8-MG-BA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLXTWM2OD1yLkK1JI5O NYTr[Yh6W0GQR1XS
KNS-42 NEHqTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvXYJKSzVyPUCuNlU5KG6P NG\5ZY9USU6JRWK=
LXF-289 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnHVXNKSzVyPUCuNlY6KG6P M4PC[HNCVkeHUh?=
OVCAR-4 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P3UGlEPTB;MD6yPFkhdk1? M3TRcHNCVkeHUh?=
LOUCY Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrRS|lKSzVyPUCuNlk{KG6P NUjSfppTW0GQR1XS
BB65-RCC NUmwXJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDVTWM2OD1yLkOwOEBvVQ>? MU\TRW5ITVJ?
D-542MG NFn3d2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwM{K5JI5O MUPTRW5ITVJ?
ONS-76 NIS2[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7qUoRKSzVyPUCuN|Mhdk1? MV\TRW5ITVJ?
BB30-HNC M4j3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYfHo2UUN3ME2wMlM{PSCwTR?= NH3vXoxUSU6JRWK=
KS-1 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPoSoN1UUN3ME2wMlM1KG6P MVTTRW5ITVJ?
A388 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jhe2lEPTB;MD6zOVYhdk1? MVLTRW5ITVJ?
ES8 M1;SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:z[W9RUUN3ME2wMlQhdk1? MXnTRW5ITVJ?
MZ2-MEL MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy5O5NGUUN3ME2wMlQxPyCwTR?= MUnTRW5ITVJ?
HCC2998 NIL3fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\1TWM2OD1yLkSxNkBvVQ>? NFLQVYZUSU6JRWK=
D-247MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXqbYxKSzVyPUCuOFE{KG6P NXfMcWViW0GQR1XS
ACN NEKxdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HudWlEPTB;MD60NVchdk1? MXLTRW5ITVJ?
LB2518-MEL M4K5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwNEK1JI5O M36yPHNCVkeHUh?=
ES1 M3fqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPMdI1JUUN3ME2wMlQ{KG6P MoTFV2FPT0WU
HCE-T NFXjZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vrZmlEPTB;MD60N|khdk1? M37jVHNCVkeHUh?=
OS-RC-2 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPaU4RKSzVyPUCuOFQhdk1? NUHmb21mW0GQR1XS
MFH-ino Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPkSoJTUUN3ME2wMlQ1OyCwTR?= NEnpWGVUSU6JRWK=
OCUB-M NF3iZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICwboFKSzVyPUCuOFQ4KG6P NVHYRnp5W0GQR1XS
CP66-MEL M4nBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0OWlEPTB;MD60O|Mhdk1? M3rRVHNCVkeHUh?=
LB771-HNC NUWz[FQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;TTWM2OD1yLkS3OEBvVQ>? NIHBclNUSU6JRWK=
DSH1 NUjmXlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3BTWM2OD1yLkS4JI5O NWHzOpg1W0GQR1XS
HUTU-80 NHvEO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1yLkWzN{BvVQ>? NEXmSW1USU6JRWK=
CESS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnzc4FKSzVyPUCuOVM5KG6P M4KxNXNCVkeHUh?=
NCI-H747 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vuUGlEPTB;MD61N|khdk1? NFPlVGFUSU6JRWK=
HT-144 M2iyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THc2lEPTB;MD61O|Yhdk1? MYDTRW5ITVJ?
COLO-829 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XhW2lEPTB;MD62NVQhdk1? MmHhV2FPT0WU
A4-Fuk M3TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n2NmlEPTB;MD62NlMhdk1? NF34TGFUSU6JRWK=
GI-ME-N MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD1yLk[zOEBvVQ>? M{TicHNCVkeHUh?=
LB831-BLC MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPjcYdKSzVyPUCuOlQyKG6P M4D6[XNCVkeHUh?=
HOP-62 NYHQOWlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDiZXRNUUN3ME2wMlY1PyCwTR?= NUL5dWF[W0GQR1XS
BB49-HNC NGKzclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLoNZl7UUN3ME2wMlY2OiCwTR?= MVXTRW5ITVJ?
D-336MG M4[4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInEN4NKSzVyPUCuOlU4KG6P M3rm[nNCVkeHUh?=
TK10 NH2zZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Y[XVKSzVyPUCuOlc6KG6P NXr5dXU4W0GQR1XS
Ramos-2G6-4C10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNkmzJI5O NEK4T|RUSU6JRWK=
LB373-MEL-D NH7zcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rxSmlEPTB;MD63JI5O M{TaR3NCVkeHUh?=
SF126 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUTodKSzVyPUCuO|AyKG6P NUjId2dkW0GQR1XS
UACC-257 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwN{Ggcm0> MVLTRW5ITVJ?
KINGS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTjTWM2OD1yLkeyNkBvVQ>? MmftV2FPT0WU
LS-513 M4e5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwN{O5JI5O NInpTXRUSU6JRWK=
GI-1 M1yz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ixXGlEPTB;MD63OlQhdk1? M2TtSXNCVkeHUh?=
ES7 NUPGdpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwN{[2JI5O NVrwR2RVW0GQR1XS
LB2241-RCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr4V4FKSzVyPUCuPFA1KG6P M{LkOHNCVkeHUh?=
D-263MG M3;0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LBTGlEPTB;MD64NFchdk1? NUjVfVRRW0GQR1XS
SW684 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHYTWM2OD1yLkiyNUBvVQ>? NF7y[4RUSU6JRWK=
ML-2 M4Pxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;MeppKSzVyPUCuPFIyKG6P NFPEOHRUSU6JRWK=
SK-LMS-1 NIL1WGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwOEW0JI5O NXrWeGlkW0GQR1XS
TE-5 NX:0e29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzWJE1UUN3ME2wMlg3PSCwTR?= M2HNdnNCVkeHUh?=
QIMR-WIL MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmwR5hCUUN3ME2wMlg5QSCwTR?= Ml3PV2FPT0WU
NCI-H1355 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWyTWM2OD1yLki5OUBvVQ>? NWLDXXV[W0GQR1XS
SNB75 NF;OZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fKeWlEPTB;MD65NVIhdk1? MnnQV2FPT0WU
RXF393 M3ja[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPmXGlvUUN3ME2wMlkyPCCwTR?= MXvTRW5ITVJ?
IST-MEL1 M1nncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwOUG3JI5O NGrJ[lBUSU6JRWK=
SF268 NXrKZYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvTOJJOUUN3ME2wMlkzOyCwTR?= Mmr5V2FPT0WU
KALS-1 NHLJOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMZmpKSzVyPUCuPVI2KG6P NEizTmhUSU6JRWK=
HC-1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwOUe1JI5O NFTtT2RUSU6JRWK=
SW872 NF7IZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH5TJVKSzVyPUCuPVk3KG6P MmO0V2FPT0WU
PSN1 NFLDVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvMTWM2OD1zLkCxJI5O NH70empUSU6JRWK=
TE-1 NYXR[5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwMEOgcm0> MkO1V2FPT0WU
TE-10 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Tb3RKSzVyPUGuNFMhdk1? MlfGV2FPT0WU
RKO MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;CO4lKSzVyPUGuNFYhdk1? NF:4Z5ZUSU6JRWK=
LC-2-ad MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\WZ2lEPTB;MT6wPEBvVQ>? M4rE[3NCVkeHUh?=
SK-MM-2 NIrXfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nVeGlEPTB;MT6wPUBvVQ>? NWXz[45WW0GQR1XS
VA-ES-BJ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD1zLkC5JI5O NVTrNWJMW0GQR1XS
MZ7-mel MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGwe2dsUUN3ME2xMlA6KG6P MlHWV2FPT0WU
D-392MG MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37VbWlEPTB;MT6xJI5O MUHTRW5ITVJ?
CCRF-CEM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXuXIVKSzVyPUGuNVMhdk1? MmnlV2FPT0WU
EM-2 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD1zLkG2JI5O MYnTRW5ITVJ?
HAL-01 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMUigcm0> M{PsZnNCVkeHUh?=
TE-8 NYPsTnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvOWHNKSzVyPUGuNVkhdk1? MXvTRW5ITVJ?
NCI-H1882 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNSIpKSzVyPUGuNkBvVQ>? M3\1R3NCVkeHUh?=
Daudi NHHk[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwMkKgcm0> MX7TRW5ITVJ?
BL-41 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLJTWM2OD1zLkK1JI5O MnXqV2FPT0WU
SR M3:1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPUTWM2OD1zLkK1JI5O NYizXnFqW0GQR1XS
KM12 NHHnVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPVNnRKSzVyPUGuNlchdk1? NEDLe2xUSU6JRWK=
K5 NWrVbIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD1zLkK4JI5O NGj1cHBUSU6JRWK=
A3-KAW Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1zLkK4JI5O MlnMV2FPT0WU
CMK MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwMkmgcm0> NGXIUnZUSU6JRWK=
Calu-6 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHrTWM2OD1zLkK5JI5O M{iwfHNCVkeHUh?=
IST-SL2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrJVZJKSzVyPUGuN|Ehdk1? NHPJ[IRUSU6JRWK=
OPM-2 NG[x[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX5VHRiUUN3ME2xMlM{KG6P NUPOVoJ7W0GQR1XS
DU-4475 NX3kb3Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP5TWM2OD1zLkO2JI5O NFnGbnVUSU6JRWK=
ECC12 M3S3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXubYxHUUN3ME2xMlM4KG6P M{XXUnNCVkeHUh?=
L-540 M4jSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnyR|JKSzVyPUGuN|chdk1? Mn[zV2FPT0WU
CAS-1 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwM{egcm0> MnrjV2FPT0WU
PF-382 NHfP[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz6RZNZUUN3ME2xMlQ4KG6P MnPUV2FPT0WU
LS-411N NGDYV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XvRmlEPTB;MT61N{BvVQ>? MnqwV2FPT0WU
NCI-H69 NFXaVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj1[|R{UUN3ME2xMlU1KG6P M171R3NCVkeHUh?=
NB12 NXSxVm5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwNU[gcm0> NIHNfHdUSU6JRWK=
HEL NESyTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjWfJFqUUN3ME2xMlYyKG6P NUWyZWxXW0GQR1XS
GCIY MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1eyZ2lEPTB;MT62NkBvVQ>? NYDvWGN4W0GQR1XS
EHEB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL0eWJEUUN3ME2xMlY4KG6P MmHZV2FPT0WU
TGBC1TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwN{Ggcm0> MXjTRW5ITVJ?
KURAMOCHI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxfGlEPTB;MT63NkBvVQ>? MWHTRW5ITVJ?
U-266 NUT0OlhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfINVRKSzVyPUGuO|Yhdk1? NWPSdpNCW0GQR1XS
LC4-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrITWM2OD1zLke5JI5O NVK1VY9{W0GQR1XS
NCI-H2126 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwODDuUS=> M2PLOHNCVkeHUh?=
NCI-H1092 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTRZl2UUN3ME2xMlghdk1? NGn3TI1USU6JRWK=
GB-1 M3nNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPDSWhKSzVyPUGuPFEhdk1? NWrzOIJrW0GQR1XS
MV-4-11 NXnOUJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPWTWM2OD1zLkiyJI5O MnXpV2FPT0WU
Becker MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHvTWM2OD1zLkizJI5O NHKzUWZUSU6JRWK=
MPP-89 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3VXYxKSzVyPUGuPFkhdk1? NY[0XotyW0GQR1XS
BE-13 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nnPWlEPTB;MT65N{BvVQ>? MWXTRW5ITVJ?
697 NYXPdVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwOUmgcm0> NWDuSZB{W0GQR1XS
NKM-1 M{LGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwZWpnUUN3ME2yJI5O NHLnXXdUSU6JRWK=
NB13 M{fHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJibl2= MoHMV2FPT0WU
LS-123 NF\xNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKT2V3UUN3ME2yMlAzKG6P MUnTRW5ITVJ?
NB17 NHzEU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jMZmlEPTB;Mj6wOEBvVQ>? NWrYTWhRW0GQR1XS
LAN-6 NGW5ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\UemF7UUN3ME2yMlA2KG6P M1\mW3NCVkeHUh?=
EW-24 NW\QUlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwMEigcm0> NEf2O2hUSU6JRWK=
NOS-1 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPZe4dKSzVyPUKuNVEhdk1? M{H3eHNCVkeHUh?=
BL-70 M{DQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTkTHJKSzVyPUKuNVIhdk1? MnqzV2FPT0WU
GT3TKB NV7scXNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5TWM2OD1{LkGyJI5O NWjFdW9YW0GQR1XS
HH NVfhdZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTGTWM2OD1{LkGzJI5O NVuzUmM1W0GQR1XS
KE-37 NEDtSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwMUOgcm0> NGXYSZRUSU6JRWK=
MOLT-4 NYTlXFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\VbmlEPTB;Mj6xN{BvVQ>? NHO0ZVRUSU6JRWK=
EKVX MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMUSgcm0> MYPTRW5ITVJ?
KGN M2fWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\RW|M3UUN3ME2yMlE2KG6P NInK[Y5USU6JRWK=
ES4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HpSGlEPTB;Mj6xOkBvVQ>? MUHTRW5ITVJ?
SJSA-1 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTR[|VMUUN3ME2yMlIyKG6P M1LsRXNCVkeHUh?=
KMOE-2 M2X0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCToh[UUN3ME2yMlI{KG6P M3\QZnNCVkeHUh?=
NB5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\5TWM2OD1{LkK3JI5O MWLTRW5ITVJ?
BC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnoNWNxUUN3ME2yMlMyKG6P NVzDZ3p6W0GQR1XS
NB10 NE\RU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwM{Kgcm0> NWHZbIN6W0GQR1XS
RPMI-8226 NIe3[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PXTWlEPTB;Mj6zOUBvVQ>? MVTTRW5ITVJ?
SCC-3 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLKPYJTUUN3ME2yMlM4KG6P M{X4VnNCVkeHUh?=
ARH-77 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvYTWM2OD1{LkO4JI5O MoLvV2FPT0WU
NCI-H748 M2roU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTZe2RbUUN3ME2yMlM6KG6P NHXKVlVUSU6JRWK=
KU812 NYi4[IJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHpcGVKSzVyPUKuOFIhdk1? NHHuXJRUSU6JRWK=
NCI-H64 NVL1e|JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNESgcm0> M3XtUXNCVkeHUh?=
NB69 M3jMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELTbXhKSzVyPUKuOFYhdk1? NUPBPGFvW0GQR1XS
KNS-81-FD MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvpTWM2OD1{LkS4JI5O MY\TRW5ITVJ?
LB1047-RCC NWTW[4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33zV2lEPTB;Mj61O{BvVQ>? MX;TRW5ITVJ?
EB-3 NGHMZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwNk[gcm0> M4fkRXNCVkeHUh?=
Mo-T MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLTWM2OD1{Lke0JI5O MkGyV2FPT0WU
EW-16 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XWZ2lEPTB;Mj63OUBvVQ>? MnOyV2FPT0WU
CTV-1 NGnKbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjWTpZKSzVyPUKuPEBvVQ>? NFnKW5RUSU6JRWK=
ETK-1 M2flSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Xe2lEPTB;Mj64OEBvVQ>? MX7TRW5ITVJ?
C2BBe1 M{nQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\wNmlEPTB;Mj64PUBvVQ>? NWK3OmpnW0GQR1XS
MOLT-16 NYjuPHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHpTWM2OD1{Lki5JI5O NF;oTHdUSU6JRWK=
SW954 MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD1{Lkmgcm0> MU\TRW5ITVJ?
HT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwMEKgcm0> NWnLSmZqW0GQR1XS
KARPAS-299 M2PvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNwME[gcm0> MWrTRW5ITVJ?
MONO-MAC-6 NWe1N5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD1|LkGgcm0> M2G1UXNCVkeHUh?=
CGTH-W-1 NU\WO3FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WwbWlEPTB;Mz6xJI5O M1zCZnNCVkeHUh?=
SK-PN-DW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nkNGlEPTB;Mz6xOEBvVQ>? NILFZ5RUSU6JRWK=
CW-2 M2XqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTNwMkGgcm0> M4nM[XNCVkeHUh?=
SK-N-DZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D0[WlEPTB;Mz6yOkBvVQ>? NXPTSI4yW0GQR1XS
NEC8 M2\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzVTWM2OD1|LkO1JI5O M3fCb3NCVkeHUh?=
LB996-RCC NXPMZZU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNDDuUS=> MXvTRW5ITVJ?
DB MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvBbnJKSzVyPUOuOFEhdk1? MXzTRW5ITVJ?
TE-15 NXTIcXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHoXWhKSzVyPUOuOFMhdk1? NIHTcnpUSU6JRWK=
COR-L88 NFvGdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mxXWlEPTB;Mz60O{BvVQ>? M2noVHNCVkeHUh?=
LAMA-84 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwNEmgcm0> NH3xcGdUSU6JRWK=
MEG-01 M4TVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNwNEmgcm0> M4[xWnNCVkeHUh?=
LOXIMVI NXrFd2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7iSJNuUUN3ME2zMlUhdk1? Mn;SV2FPT0WU
RPMI-8402 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzcHRKSzVyPUOuOUBvVQ>? MVjTRW5ITVJ?
KARPAS-45 NYm1XXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGzcYRKSzVyPUOuOVQhdk1? M1frR3NCVkeHUh?=
HCC1187 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jtXmlEPTB;Mz61OEBvVQ>? MnHTV2FPT0WU
MZ1-PC NF;ldpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPldFNKSzVyPUOuOVQhdk1? MUDTRW5ITVJ?
no-11 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hue2lEPTB;Mz61OUBvVQ>? M3y4VHNCVkeHUh?=
EVSA-T MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\TR5VKSzVyPUOuOkBvVQ>? M{fDXHNCVkeHUh?=
DJM-1 NELYW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTQTWM2OD1|Lk[zJI5O NVvwfJpKW0GQR1XS
COLO-684 NIXmU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nGTmlEPTB;Mz62OkBvVQ>? NIXXd2pUSU6JRWK=
NMC-G1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;5TIl{UUN3ME2zMlY5KG6P NHHyfpJUSU6JRWK=
LC-1F MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwN{Sgcm0> MVjTRW5ITVJ?
RL95-2 M2DjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;pTWM2OD1|Lke5JI5O NVjIZ2dCW0GQR1XS
COLO-320-HSR M{nLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG4Z2hKSzVyPUOuPVIhdk1? NIjV[IRUSU6JRWK=
RCC10RGB NGrsO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm5TWM2OD1|LkmzJI5O MULTRW5ITVJ?
HD-MY-Z MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD1|LkmzJI5O NXvw[VZrW0GQR1XS
NCI-H2141 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwMEWgcm0> NFvqVolUSU6JRWK=
K-562 NHfxTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD12LkGyJI5O M4faWXNCVkeHUh?=
NCI-H1648 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnxXZpkUUN3ME20MlE{KG6P NHm2ZYVUSU6JRWK=
OMC-1 NGDRSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rycWlEPTB;ND6xPEBvVQ>? MkPxV2FPT0WU
LB647-SCLC NUL6TGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMkKgcm0> NYnJbIF7W0GQR1XS
TE-12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfES3ZkUUN3ME20MlI2KG6P NH\EcnpUSU6JRWK=
NOMO-1 NFW5U2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XLV2lEPTB;ND6zN{BvVQ>? NUD6S5FOW0GQR1XS
Raji MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITuS29KSzVyPUSuOFYhdk1? NWjVVIdqW0GQR1XS
NALM-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETDOmZKSzVyPUSuOFkhdk1? MmnNV2FPT0WU
HL-60 M2foW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XSXGlEPTB;ND62O{BvVQ>? M4mybnNCVkeHUh?=
IST-SL1 M4i0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;NcolKSzVyPUSuOlghdk1? Ml34V2FPT0WU
MHH-PREB-1 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13L[2lEPTB;ND64OkBvVQ>? MV3TRW5ITVJ?
MHH-NB-11 M4LlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M365Z2lEPTB;ND65NUBvVQ>? NVTVeFhkW0GQR1XS
JiyoyeP-2003 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGxbWZKSzVyPUWgcm0> NEfnd3RUSU6JRWK=
SBC-1 M4PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12yNWlEPTB;NT6wNUBvVQ>? M1exRXNCVkeHUh?=
CHP-126 NIr1bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6OWlEPTB;NT6wOkBvVQ>? NV3S[IF[W0GQR1XS
LU-139 NXuxWIg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq1TY83UUN3ME21MlE{KG6P NYTEVVhqW0GQR1XS
NCI-SNU-5 NIXzTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTVwMUegcm0> MWrTRW5ITVJ?
SW962 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDPdmpKSzVyPUWuNlEhdk1? MmXTV2FPT0WU
EW-1 M4TPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TvbmlEPTB;NT6zNUBvVQ>? MoHKV2FPT0WU
NCI-H1417 NVXsUpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTVwNUGgcm0> M13JWHNCVkeHUh?=
LU-65 M4HkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QO2lEPTB;NT64OEBvVQ>? NFX6V|RUSU6JRWK=
D-502MG NES4T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDLW3BKSzVyPU[uN|chdk1? Mnn4V2FPT0WU
BC-3 NH\QWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwNkGgcm0> MmH4V2FPT0WU
GDM-1 M1m4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e0RmlEPTB;Nj63O{BvVQ>? MULTRW5ITVJ?
NCI-H2196 M3n2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[yTWM2OD14Lkigcm0> MnLOV2FPT0WU
NB1 NUTib2M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4TWM2OD14Lki4JI5O M{KwPHNCVkeHUh?=
NCI-H345 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzhO5dlUUN3ME23MlIhdk1? Mme0V2FPT0WU
SU-DHL-1 NXTpOVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LCWWlEPTB;Nz6yOEBvVQ>? NU\4bXJiW0GQR1XS
JVM-2 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfOTWM2OD15LkK4JI5O Ml\PV2FPT0WU
LU-134-A M3rYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKOmlEPTB;Nz6zPUBvVQ>? MXzTRW5ITVJ?
NCI-H1694 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDaTWM2OD15LkW4JI5O NIHOUIpUSU6JRWK=
NCI-SNU-16 NWHMTlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwNkWgcm0> NUPTTZByW0GQR1XS
L-363 NVfjPW52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT0PVJKSzVyPUeuO{BvVQ>? MnXFV2FPT0WU
KG-1 NHT0folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\yTWM2OD15Lkm0JI5O MmDzV2FPT0WU
MN-60 M2L6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX4bY5KSzVyPUiuNVQhdk1? MVrTRW5ITVJ?
NB6 NWjyNlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrvTWM2OD16LkS4JI5O MYDTRW5ITVJ?
MLMA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD16Lki1JI5O NXfMUoJ[W0GQR1XS
ATN-1 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf3TWM2OD16Lki5JI5O NHG3R2dUSU6JRWK=
SK-NEP-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTq[mxQUUN3ME25MlAyKG6P NXnyc2xPW0GQR1XS
DMS-114 M{LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PkSWlEPTB;OT62NkBvVQ>? MlPOV2FPT0WU
CTB-1 NGXLS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\RTWM2OD17Lk[3JI5O MYDTRW5ITVJ?
NCI-H2081 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C0bWlEPTB;MUCuNFkhdk1? NW\vWnNpW0GQR1XS
ES5 NHH3cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\YU4hKSzVyPUGwMlM5KG6P M1rLdHNCVkeHUh?=
HCC1599 NWfER2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFzLkmxJI5O NVHvSWlrW0GQR1XS
NCI-H23 NVfac2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjyTWM2OD1zMj6xNkBvVQ>? MlvHV2FPT0WU
NCI-H1581 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXhTWM2OD1zMj6yPEBvVQ>? MoTlV2FPT0WU
JVM-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1zMj65PUBvVQ>? NVzrRZpJW0GQR1XS
NCI-SNU-1 NVPYcJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\kVmpKSzVyPUGzMlE6KG6P MkP2V2FPT0WU
NB7 NIjxenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXyTWM2OD1zNT65NkBvVQ>? NFrUdHNUSU6JRWK=
JAR M4W2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF4LkGzJI5O MkDFV2FPT0WU
TGW M4jvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF4LkS4JI5O MmTqV2FPT0WU
U-87-MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TNOmlEPTB;MU[uO|Yhdk1? NIi0UG1USU6JRWK=
NCI-H1436 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvj[FNKSzVyPUG3MlAyKG6P Mny5V2FPT0WU
GOTO MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfUZY1KSzVyPUG3MlA3KG6P Mnf0V2FPT0WU
COLO-800 M1KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTQTWM2OD1zNz62OEBvVQ>? NF6ybI9USU6JRWK=
MFM-223 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF5LkmxJI5O MWfTRW5ITVJ?
EW-18 M4HxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Be2lEPTB;MUeuPVYhdk1? MYLTRW5ITVJ?
NB14 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjCZ41DUUN3ME2xO{46QCCwTR?= MXvTRW5ITVJ?
EB2 M4DKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrPcHpKSzVyPUG4MlA5KG6P Mm\sV2FPT0WU
EoL-1- NGPSR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SycWlEPTB;MUiuN|Ehdk1? NHrZNHVUSU6JRWK=
NCCIT NUnJclRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi3OXdKSzVyPUG4MlM3KG6P NFu5TphUSU6JRWK=
DG-75 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfBOG5CUUN3ME2xPE43OSCwTR?= MlX5V2FPT0WU
HCC2218 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF7LkWgcm0> NFPOb3pUSU6JRWK=
TE-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJyLkC4JI5O M3nUeXNCVkeHUh?=
SF539 NYrVTG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJyLk[3JI5O MVHTRW5ITVJ?
NCI-H446 M4Xz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJzLkG4JI5O NYnjcVBRW0GQR1XS
IST-MES1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T4e2lEPTB;MkKuO|chdk1? NUj3emtxW0GQR1XS
NCI-H82 NFHLOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0UWlEPTB;MkOuNFIhdk1? MYXTRW5ITVJ?
HCC2157 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLSTWM2OD1{Mz6xN{BvVQ>? NIrkZ2FUSU6JRWK=
EW-12 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfYTWM2OD1{Mz6xO{BvVQ>? MkT4V2FPT0WU
SIMA NWnoNFRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1{Mz6zPEBvVQ>? MX3TRW5ITVJ?
DOHH-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ|LkS1JI5O MnnQV2FPT0WU
IM-9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nRcmlEPTB;MkOuOVQhdk1? Mkm2V2FPT0WU
EC-GI-10 M1nLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HEd2lEPTB;MkSuNlMhdk1? M{XRenNCVkeHUh?=
HDLM-2 M3TQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1{ND61OEBvVQ>? Mm\GV2FPT0WU
LS-1034 NF;1cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnzOo5zUUN3ME2yOU44PSCwTR?= NYrrOJlSW0GQR1XS
REH MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ4LkSxJI5O NULKcIZmW0GQR1XS
LU-165 NUnJUohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ4LkeyJI5O M3LrXXNCVkeHUh?=
NH-12 M{TCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ5Lk[3JI5O NVS5OnJTW0GQR1XS
WSU-NHL MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ6LkO5JI5O MUnTRW5ITVJ?
ECC4 M1zxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ6Lke5JI5O NWW3cnNNW0GQR1XS
OCI-AML2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ7Lk[5JI5O MkHsV2FPT0WU
EW-3 NYfwbYJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LHTGlEPTB;M{CuOVkhdk1? NGnyZmZUSU6JRWK=
NCI-H526 M3;yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTlOWJlUUN3ME2zNk42PCCwTR?= MlmzV2FPT0WU
NCI-H719 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN2LkOxJI5O NXjWNGgxW0GQR1XS
KARPAS-422 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1SGlEPTB;M{WuNFQhdk1? NVz4e29sW0GQR1XS
SK-MEL-1 NI\n[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN3LkG3JI5O NV:zSHBuW0GQR1XS
ES3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jyT2lEPTB;M{WuNVkhdk1? NELCSoNUSU6JRWK=
UACC-812 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\GemlEPTB;M{WuOFQhdk1? M1G3bnNCVkeHUh?=
C8166 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN3Lkegcm0> NUjrTWdjW0GQR1XS
MDA-MB-134-VI NUHU[2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnWTWM2OD1|NT64O{BvVQ>? NUfjR4F7W0GQR1XS
D-283MED NVzldXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HuWmlEPTB;M{euO|khdk1? NVvxeHhkW0GQR1XS
SHP-77 M2nqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvZ[HJKSzVyPUO4MlA{KG6P MVzTRW5ITVJ?
NCI-H2227 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfmT2xKSzVyPUSwMlQ6KG6P M2jCS3NCVkeHUh?=
SKM-1 NVLzNVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorxTWM2OD12Mj62N{BvVQ>? MnPGV2FPT0WU
L-428 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\BUotrUUN3ME20N{45PiCwTR?= NFfQVGZUSU6JRWK=
RPMI-6666 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DqOWlEPTB;NEWuPFkhdk1? Mn63V2FPT0WU
NCI-H716 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR6LkixJI5O NFzvPXNUSU6JRWK=
DMS-79 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewXWFKSzVyPUWwMlcyKG6P MlTjV2FPT0WU
RS4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lj[2lEPTB;NUCuPFghdk1? NV;KOHRoW0GQR1XS
NCI-H720 M3rlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPie2c5UUN3ME21NU4yOSCwTR?= NXPocXdYW0GQR1XS
MC-CAR M2f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhTWM2OD13MT61NkBvVQ>? NVTVRYhHW0GQR1XS
TALL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjJcYdkUUN3ME21N{46OSCwTR?= MVTTRW5ITVJ?
NCI-N87 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrofnJKSzVyPUW0MlE5KG6P MUHTRW5ITVJ?
P30-OHK M3jvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iwcmlEPTB;NUSuOlEhdk1? M3rDWnNCVkeHUh?=
LP-1 NH:xdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTZzLkK4JI5O M4e5XHNCVkeHUh?=
YT NWD4bXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnMelFKSzVyPU[xMlghdk1? MonNV2FPT0WU
MRK-nu-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxUI9uUUN3ME22NU45OiCwTR?= NUnZdVJJW0GQR1XS
BT-474 NHLaRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PqcmlEPTB;NkWgcm0> NIrqVmdUSU6JRWK=
NCI-H322M M1P2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HVNmlEPTB;Nk[uNVEhdk1? MljUV2FPT0WU
NCI-H128 NIHhPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzdGlEPTB;N{SuO|chdk1? NUX5R|RzW0GQR1XS
KMS-12-PE Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxbGlEPTB;N{[uNlQhdk1? NWXERYE4W0GQR1XS
KP-N-YS NUHXTpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHQZYxnUUN3ME23Ok44PCCwTR?= NF[3T3JUSU6JRWK=
ALL-PO NV\4SpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHoXHc1UUN3ME23O{43PiCwTR?= MX\TRW5ITVJ?
EW-13 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTd5Lke2JI5O NWjKdGV5W0GQR1XS
EW-11 NUL0dnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjrTWM2OD15OD61NkBvVQ>? M2nlUnNCVkeHUh?=
SK-N-FI NGK4bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKyUWJKSzVyPUiwMlIhdk1? MmPKV2FPT0WU
CAL-148 NF;mZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvEe2NKSzVyPUixMlg1KG6P NFrh[oZUSU6JRWK=
RL Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXkTWM2OD16Nj6wPUBvVQ>? NYnqV3J5W0GQR1XS
AM-38 M13NbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonGTWM2OD16OD6wPEBvVQ>? MVzTRW5ITVJ?
RH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fM[2lEPTB;OUmuPFUhdk1? NFTtem1USU6JRWK=
NCI-H1770 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXl[oNSUUN3ME2xNFIvPDlibl2= NFvPeGpUSU6JRWK=
SIG-M5 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HpbWlEPTB;MUC1MlA3KG6P MkXIV2FPT0WU
GR-ST NV7hfGY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTrTWM2OD1zMUOuN|Qhdk1? Mn\SV2FPT0WU
ST486 M1LQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ryXmlEPTB;MUG0MlA3KG6P M2nDS3NCVkeHUh?=
NCI-H1650 M1u2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjjc3hrUUN3ME2xNVUvOjlibl2= MWHTRW5ITVJ?
MHH-CALL-2 NETjXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLHTWM2OD1zMUWuO{BvVQ>? MnvTV2FPT0WU
BV-173 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm0dJBKSzVyPUGyNk44OSCwTR?= NVLYcHRuW0GQR1XS
MC116 MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPIb4ZKSzVyPUG0PE45PSCwTR?= MXjTRW5ITVJ?
NCI-H524 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnFTFZKSzVyPUG1PU4yKG6P MVzTRW5ITVJ?
SCLC-21H NUXhcWJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXud4xKSzVyPUG1PU41OSCwTR?= NVTkO4Y2W0GQR1XS
NCI-H1304 NX20dWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfoR3BUUUN3ME2xOlkvOjFibl2= NInaT4xUSU6JRWK=
NCI-H510A M1S4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF6NT6zO{BvVQ>? NEflNnBUSU6JRWK=
NCI-H209 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7Nj61NkBvVQ>? MlWwV2FPT0WU
KM-H2 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nqd2lEPTB;MUm3MlA2KG6P M4\vUHNCVkeHUh?=
NCI-H1395 NUXzRnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzMD6xN{BvVQ>? MVvTRW5ITVJ?
NCI-H1155 NWL0e5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRdmFKSzVyPUKzNE4{OiCwTR?= MmXHV2FPT0WU
COR-L279 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD1{NUKuNVchdk1? NV3iWZF4W0GQR1XS
NCI-H1299 NEjJSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G3[2lEPTB;Mk[xMlcyKG6P MmjBV2FPT0WU
EW-22 NF;jR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ4Mz63OUBvVQ>? NFTVR4pUSU6JRWK=
SK-MEL-2 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrIWoJ[UUN3ME2yPFEvQSCwTR?= MWDTRW5ITVJ?
KASUMI-1 NWLI[HZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\V[GlEPTB;MkizMlA2KG6P NEPqd3hUSU6JRWK=
NCI-H187 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPxbYlmUUN3ME2yPFcvODhibl2= MoHGV2FPT0WU
NCI-H2171 NFu2WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXZWlEPTB;Mki4MlkzKG6P NFr6OIdUSU6JRWK=
LNCaP-Clone-FGC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LxTWlEPTB;Mkm1MlI3KG6P MlrWV2FPT0WU
NCI-H1522 NETWU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNyNz6wOUBvVQ>? NX3HfoQ6W0GQR1XS
SCH MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPz[YJ5UUN3ME2zNlIvOjJibl2= MkHWV2FPT0WU
THP-1 M{PiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN{Mj62JI5O M1j3[nNCVkeHUh?=
SNU-C1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN4Mj6wPUBvVQ>? NX\rRnJzW0GQR1XS
CA46 NI\nd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrlTWM2OD1|N{OuOlMhdk1? NX7SXZY{W0GQR1XS
NCI-H1963 NUDSSYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTN6Nj6xPUBvVQ>? NGj5[pZUSU6JRWK=
DEL NV3QXHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vCWWlEPTB;M{mxMlI4KG6P MULTRW5ITVJ?
TUR NHrHVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH4TWM2OD1|OU[uOlEhdk1? NY[1OIsxW0GQR1XS
NCI-H226 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:zTWM2OD12MEOuNlMhdk1? NYLGNYM6W0GQR1XS
COLO-668 NWfXWpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;yN|A5UUN3ME20NFMvPTdibl2= MXTTRW5ITVJ?
CPC-N MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX4fFBKSzVyPUSwN{44PyCwTR?= MmjRV2FPT0WU
NCI-H889 NGHjU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXIbIlKSzVyPUS2NU46OiCwTR?= MXjTRW5ITVJ?
J-RT3-T3-5 NGnFdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LPO2lEPTB;NUOyMlU4KG6P MlvtV2FPT0WU
MSTO-211H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD13N{SuNlYhdk1? MXHTRW5ITVJ?
SCC-15 NYHhc|RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZ4Nz60O{BvVQ>? NVXxVmU6W0GQR1XS
SUP-T1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPWTWM2OD14OE[uNFQhdk1? M4TFUXNCVkeHUh?=
DMS-153 NYLQVlFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\oTWM2OD15NE[uPFMhdk1? M1SwR3NCVkeHUh?=
MS-1 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWeXNKSzVyPUe1PU41OiCwTR?= M3zVcHNCVkeHUh?=
TC-YIK Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorxTWM2OD15OEGuNFEhdk1? MVjTRW5ITVJ?
RPMI-8866 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDBSWFKSzVyPUGwNFYvOjhizszN MX7TRW5ITVJ?
KY821 NVTieplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjKSmRKSzVyPUGwN|YvODRizszN NGLPUYVUSU6JRWK=
P31-FUJ M{XIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\pWWlEPTB;MUGxNk44PSEQvF2= NWHJd5duW0GQR1XS
COLO-824 NGOyN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLyTG9KSzVyPUGyOlEvPzhizszN MlewV2FPT0WU
U-698-M M3ziVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[0cVUxUUN3ME2yNlYzNjF3IN88US=> M2q5RnNCVkeHUh?=
TE-441-T NGrodW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG1TWM2OD1{NUKxMlch|ryP NV7v[pVNW0GQR1XS
IMR-5 NXPWWXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe4PWFtUUN3ME2zOFA6NjZ{IN88US=> MmXoV2FPT0WU
NCI-H1838 M2PON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRzOE[uN|Ih|ryP NUDPdFBKW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID